Why is Brawn Biotech falling/rising?

As of 12-Sep, Brawn Biotech Ltd's stock price is currently at 20.80, reflecting an increase of 0.99 or 5.0%. The stock has been gaining momentum, having outperformed its sector by 5.71% today and achieving a consecutive gain over the last three days, resulting in a total return of 9.42% during this period. However, despite this positive short-term performance, the company faces significant challenges, including weak long-term fundamental strength, as indicated by an average Return on Equity (ROE) of 0% and declining net sales and operating profit over the past five years. Additionally, the stock is considered risky due to a negative EBITDA and poor ability to service its debt, which could undermine investor confidence.
In the broader market context, Brawn Biotech's recent performance contrasts with the Sensex, which has shown a 1.48% increase over the past week. While the stock has outperformed the sector in the short term, its one-week return of -0.67% indicates a struggle to maintain momentum compared to the benchmark. Furthermore, the stock's year-to-date performance is down by 2.39%, while the Sensex has gained 4.82%, highlighting the challenges Brawn Biotech faces in attracting investor interest amidst its financial difficulties.